SURTAVI Results Confirmed: TAVR Similar to Surgery in Intermediate-risk Patients
A final analysis of 24-month results from the SURTAVI trial confirmed interim findings that transcatheter aortic valve replacement (AVR) with a self-expanding bioprosthesis had similar outcomes versus surgical AVR in patients at intermediate risk for surgery. As Cardiology Today’s Intervention previously reported, in the interim 24-month analysis published in March 2017, patients who had TAVR with a self-expanding valve (CoreValve or Evolut R, Medtronic) had similar rates of death or disabling stroke as patients who underwent surgery.
7701 Las Colinas Blvd., Ste. 800, Irving, TX 75063